Compounds > pilocarpine
Page last updated: 2024-08-17

pilocarpine and bumetanide

pilocarpine has been researched along with bumetanide in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's8 (80.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Brandt, C; Heuchert, N; Löscher, W; Nozadze, M; Rattka, M1
Aertsen, A; Barmashenko, G; Hefft, S; Kirschstein, T; Köhling, R1
Brandt, C; Erker, T; Löscher, W; Töllner, K1
Brandt, C; Erker, T; Löscher, W; Schidlitzki, A; Schreppel, P; Töllner, K; Twele, F1
Gailus, B; Gericke, B; Hampel, P; Johne, M; Kaczmarek, E; Löscher, W; Römermann, K1

Reviews

1 review(s) available for pilocarpine and bumetanide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

9 other study(ies) available for pilocarpine and bumetanide

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010, Jun-23, Volume: 30, Issue:25

    Topics: Amygdala; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Bumetanide; Cell Count; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Epilepsy, Temporal Lobe; Female; Hippocampus; Immunohistochemistry; Motor Activity; Neurons; Phenobarbital; Pilocarpine; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 2; Status Epilepticus

2010
Positive shifts of the GABAA receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus.
    Epilepsia, 2011, Volume: 52, Issue:9

    Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Analysis of Variance; Animals; Biophysical Phenomena; Bumetanide; Chlorides; Disease Models, Animal; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; Furosemide; Gene Expression Regulation; Hippocampus; Homeostasis; In Vitro Techniques; Inhibitory Postsynaptic Potentials; K Cl- Cotransporters; Male; Membrane Potentials; Neurons; Patch-Clamp Techniques; Pilocarpine; Rats; Rats, Wistar; Receptors, GABA-A; RNA, Messenger; Sodium Potassium Chloride Symporter Inhibitors; Status Epilepticus; Symporters

2011
Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models.
    European journal of pharmacology, 2015, Jan-05, Volume: 746

    Topics: Animals; Anticonvulsants; Basolateral Nuclear Complex; Bumetanide; Disease Models, Animal; Drug Synergism; Electric Stimulation; Kainic Acid; Lithium; Male; Phenobarbital; Pilocarpine; Rats; Rats, Sprague-Dawley; Status Epilepticus

2015
The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice.
    Epilepsia, 2016, Volume: 57, Issue:5

    Topics: Animals; Anticonvulsants; Bumetanide; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Electroencephalography; Electroshock; Epilepsy, Temporal Lobe; Mice; Pentylenetetrazole; Phenobarbital; Pilocarpine; Prodrugs

2016
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
    Neuropharmacology, 2021, 03-01, Volume: 185

    Topics: Animals; Anticonvulsants; Bumetanide; Drug Therapy, Combination; Epilepsy; Female; Mice; Phenobarbital; Pilocarpine; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide; Treatment Outcome

2021